AB-3A4: A novel KAAG1-targeting antibody-drug conjugate is active in models of ovarian carcinoma, triple-negative breast cancer and castration-resistant prostate cancer. Cancer Res (2014) 74 (19_Supplement): 666.
Ref 2
First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors. Journal of Clinical Oncology 2022 40:16_suppl, TPS3157-TPS3157.